Physician profile
Owen Leftwich
NPI 1588663819
$4,059.93
in general payments reported to CMS, 2019-2025
21 companies · $844 in 2025
The $844 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $390 · 2021: $528 · 2022: $847 · 2023: $474 · 2024: $479 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $859.08 | 2022-2025 | |
| Alcon Vision LLC | $582.17 | 2019-2025 | Rocklatan, Eysuvis, Tryptyr |
| Allergan, INC. | $378.78 | 2019-2022 | |
| Oyster Point Pharma, INC. | $341.61 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $322.02 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $236.81 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $158.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $157.71 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $156.65 | 2019-2021 | |
| Dompe US, INC. | $112.54 | 2024-2025 | Oxervate |
| Ocular Therapeutix, INC. | $110.31 | 2022-2023 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $110.18 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $101.32 | 2022-2025 | Iyuzeh |
| Shire North American Group INC | $91.91 | 2019 | |
| Kala Pharmaceuticals, INC. | $88.48 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $78.81 | 2019 | |
| Rayner Intraocular Lenses Limited | $77.29 | 2023-2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Harrow Eye, LLC | $34.85 | 2025 | Vevye |
| Biotissue Holdings INC. | $22.32 | 2023 | |
| Eyevance Pharmaceuticals LLC | $21.82 | 2022 | |
| Horizon Therapeutics Plc | $17.15 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Owen Leftwich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.